Retatrutide Research

How One Peptide Engages Three Receptors

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

Retatrutide activates the GIP, GLP-1 and glucagon receptors from one sequence. All three are class B G-protein-coupled receptors within the glucagon receptor family, sharing enough structural similarity that a single engineered peptide can engage all three.

Key facts

Receptors
GIPR, GLP-1R, GCGR
Receptor class
Class B GPCRs
Family
Glucagon receptor family
Design
Balanced activity across all three
Scaffold
Modified GIP
Reference
Coskun, Cell Metab 2022

Why three receptors can share one ligand

GIP, GLP-1 and glucagon are related peptide hormones, and their receptors form a structurally related family. That common ancestry means the binding surfaces are similar enough that a sequence can be engineered to satisfy all three, not easily, but possibly. Attempting the same across unrelated receptor families would not be realistic.

Why balance is the hard problem

Similar is not identical. A substitution improving affinity at one receptor frequently reduces it at another, so the design process is a constrained optimisation across three simultaneous requirements rather than three independent ones. Coskun and colleagues describe reaching balanced activity across the three, and that balance is the achievement the paper reports.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What each receptor contributes

GLP-1 receptor agonism drives satiety and glucose-dependent insulin secretion. GIP receptor agonism adds effect through mechanisms still debated; the GIP paradox, where both agonism and antagonism appear to help, is unresolved. Glucagon receptor agonism increases energy expenditure and drives hepatic lipid oxidation, offset by the GLP-1 component's glucose-lowering effect.

Why adding glucagon is not self-defeating

Glucagon raises blood glucose, which sounds like the wrong direction. The resolution is that it also increases resting energy expenditure and mobilises hepatic fat, and with sufficient concurrent GLP-1 agonism the glycaemic effect is offset while those remain. Oxyntomodulin, an endogenous GLP-1/glucagon dual agonist, demonstrates that the body already uses this combination.

Why this produces the largest reported effect

More receptors engaged has consistently meant more weight reduction across this field: GLP-1 alone, then GLP-1 plus GIP, then all three. It has also consistently meant more gastrointestinal adverse effects, which is the trade-off the whole class shares. Retatrutide sits at the far end of both.

What remains unsettled

How much each receptor contributes. Because the three activities cannot be separated within one molecule, attributing the observed effect between them requires comparison against compounds engaging fewer receptors. That is what TRIUMPH-5, comparing retatrutide against tirzepatide, is designed to inform.

Frequently asked questions

How can one peptide activate three receptors?

GIPR, GLP-1R and GCGR belong to one structurally related family, so their binding surfaces are similar enough that an engineered sequence can satisfy all three.

Why include glucagon agonism at all?

It raises energy expenditure and mobilises hepatic fat. Sufficient GLP-1 agonism offsets its glucose-raising effect, and oxyntomodulin shows the body uses this combination naturally.

Which receptor contributes most?

Not established. The activities cannot be separated within one molecule, which is part of what a head-to-head against tirzepatide would inform.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.